Global Vaccines, Inc., P.O. Box 14827, Research Triangle Park, NC 27709, USA.
Published: January 2014
AI Article Synopsis
Article Abstract
The eradication of poliovirus from the majority of the world has been achieved through the use of two vaccines: the inactivated poliovirus vaccine (IPV) and the live-attenuated oral poliovirus vaccine (OPV). Both vaccines are effective at preventing paralytic poliomyelitis, however, they also have significant differences. Most importantly for this work is the risk of revertant virus from OPV, the greater cost of IPV, and the low mucosal immunity induced by IPV. We and others have previously described the use of an alphavirus-based adjuvant that can induce a mucosal immune response to a co-administered antigen even when delivered at a non-mucosal site. In this report, we describe the use of an alphavirus-based adjuvant (GVI3000) with IPV. The IPV-GVI3000 vaccine significantly increased systemic IgG, mucosal IgG and mucosal IgA antibody responses to all three poliovirus serotypes in mice even when administered intramuscularly. Furthermore, GVI3000 significantly increased the potency of IPV in rat potency tests as measured by poliovirus neutralizing antibodies in serum. Thus, an IPV-GVI3000 vaccine would reduce the dose of IPV needed and provide significantly improved mucosal immunity. This vaccine could be an effective tool to use in the poliovirus eradication campaign without risking the re-introduction of revertant poliovirus derived from OPV.
Introduction: following the detection of vaccine-derived poliovirus in 2019 in Ethiopia, response activities have been conducted including strengthening disease surveillance activities.
Methods: trend analysis study design of acute flaccid paralysis and measles surveillance data for the years 2021 and 2022 for Southwest Ethiopia Region was used. The non-polio acute flaccid paralysis (AFP) rate and stool adequacy rates were used to assess the AFP surveillance.
Background: Polio, a debeilitating and potentially life-threatening disease, continues to pose a risk to young children globally. While vaccination offers a powerful shield, its reach is not always equal. This study explores socioeconomic and geographical inequalities in polio immunisation coverage among two-year-olds in Sierra Leone between 2008 and 2019.
Enteroviruses (EV) are a highly diverse group of viruses multiplying primarily in the gastrointestinal tract and/or the upper respiratory tract, initially distributed in two separate genera: Enterovirus and Rhinovirus, respectively. According to the similarities in genome organization and particle structure, rhinovirus species were later reclassified as also belonging to genus Enterovirus. Human EV infections are usually asymptomatic or causing mild clinical manifestations.
The coronavirus disease 2019 (COVID-19) pandemic has disrupted polio immunization programs worldwide. The consequences of these programs' suspension were not fully presented during the COVID-19 pandemic, as some take time to present in a population. We conducted a narrative review to provide a perspective of current literature on the effect of the COVID-19 pandemic on efforts made for poliomyelitis eradication.
Background: Global efforts reduced incidence of polio cases from 350,000 in 1988 to 22 cases in 2022 globally. There have been no wild poliovirus (WPV) cases seen in Somalia since August 2014. However, in 2017, there was a surge in the number of cases of circulating vaccine-derived poliovirus type 2 (cVDPV2), even with different intervention responses using monovalent oral polio vaccine type 2 (mOPV2).
